Practical hints

Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential

Volumn , Issue , 2013, Pages 345-354

  Grotenhermen, Franjo ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85071757443     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (18)

1. Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences 1995;56(23-24):2097-2102
2. Belue RC, Howlett AC, Westlake TM, Hutchings DE. The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicology and Teratology 1995;17(1):25-30
3. Brenneisen R. Psychotrope Drogen. II. Bestimmung der Cannabinoide in Cannabis sativa L. und in Cannabisprodukten mittels Hochdruckfliissigkeitschromatographie (HPLC). [Determination of cannabinoids in Cannabis sativa L. and in cannabis products by high-performance liquid chromatography (HPLC)]. Pharmaceutica Acta Helvetiae 1984;59(9-10):247-259
4. Carta G, Gessa GL, N ava F. Dopamine D2 receptor antagonists prevent delta-9-tetrahydrocannabinol-induced antinociception in rats. European Journal of Pharmacology 1999;384(2-3): 153-156
5. Fairbairn JW, Liebmann JA, Rowan MG. The stability of cannabis and its preparations on storage. Journal of Pharmacy and Pharmacology 1976;28(1):1-7
6. Grotenhermen F, Karus M. Industrial hemp is not marijuana. Comment on the drug potential of fibre Cannabis. Journal of the I nternational Hemp Association 1999;5(2):96-101
7. Hepler RS, Petrus RS. Experiences with administration of marihuana to glaucoma patients. In Cohen S, Stillman R, eds. Therapeutic potential of marihuana. New York: Plenum, 1976
8. Hollister LE. Interactions of cannabis with other drugs in man. NIDA Research Monograph 1986;68:110-116
9. 9-THC with other drugs. In Nahas G, Sutin KM, Harvey DJ, Agurell S, eds. Marihuana and medicine. Totowa, NJ: Humana Press, 1999, pp. 273-277
10. Koe BK, Milne GM, Weissman A, Johnson MR, Melvin LS. Enhancement of brain [3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics. European Journal of Pharmacology 1985;109(2):201-212
11. Moss DE, Manderscheid PZ, Montgomery SP, Norman AB, Sanberg PR. Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette's syndrome and other motor disorders. Life Sciences 1989;44(21):1521-1525
12. Moss DE, McMaster SB, Rogers J. Tetrahydrocannabinol potentiates reserpineinduced hypokinesia. Pharmacology, Biochemistry and Behavior 1981;5(5):779-783
13. Perez-Reyes M, Burstein SH, White WR, McDonald SA, Hicks RE. Antagonism of marihuana effects by indomethacin in humans. Life Sciences 1991;48(6): 507-515
14. Perez-Reyes M. The psychologic and physiologic effects of active cannabinoids. In Nahas G, Sutin KM, Harvey DJ, Agurell S, eds. Marihuana and medicine. Totowa, NJ: Humana Press, 1999, pp. 245-252
15. Pertwee RG, Ross TM. Drugs which stimulate or facilitate central cholinergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 1991;30(1):67-71
16. Pryor GT, Husain S, Mitoma C. Acute and subacute interactions between delta-9-tetrahydrocannabinol and other drugs in the rat. Annals of the New York Academy of Sciences 1976;281:171-189
17. Sutin KM, Nahas GG. Physiological and pharmacological interactions of marihuana (Ll9-THC) with drugs and anesthetics. In Nahas G, Sutin KM, Harvey DJ, Agurell S., eds. Marihuana and medicine. Totowa, NJ: Humana Press, 1999, pp. 253-271
18. Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Research 1999;848(1-2):183-190